SGLT2 Inhibitor Dosing and Management for CKD Stages 1/2

Introduction to SGLT2 Inhibitors

The American College of Cardiology recommends standard SGLT2 inhibitor dosing for patients with CKD stages 1/2 (eGFR ≥60 mL/min/1.73 m²), with options including dapagliflozin 10 mg daily, empagliflozin 10 mg daily, or canagliflozin 100-300 mg daily 1, 2

The Kidney International guideline suggests a standard dose of dapagliflozin: 10 mg orally once daily, with no dose adjustment required for CKD stages 1/2 (eGFR ≥60 mL/min/1.73 m²) 1, 2
The Journal of the American College of Cardiology recommends a standard dose of empagliflozin: 10 mg orally once daily, with no dose adjustment required for CKD stages 1/2 (eGFR ≥60 mL/min/1.73 m²) 3, 4
The Kidney International guideline suggests a starting dose of canagliflozin: 100 mg orally once daily, which may be increased to 300 mg daily if needed for glycemic control in patients with eGFR ≥60 mL/min/1.73 m² 1, 4

SGLT2 inhibitors maintain full glucose-lowering efficacy in early CKD stages, according to the Kidney International guideline 1
The Kidney International guideline states that cardiovascular and renal protective benefits are preserved regardless of baseline kidney function 5
The Kidney International guideline recommends assessing renal function before initiating therapy and periodically thereafter 5, 2
The Kidney International guideline suggests monitoring for volume depletion, especially when used with diuretics, and considering proactive dose reduction of diuretics in patients at high risk of volume depletion 5, 2

The Kidney International guideline notes that the risk of genital mycotic infections is increased, and patients should be counseled on genital hygiene 5
The Kidney International guideline states that the risk of euglycemic diabetic ketoacidosis exists, particularly in insulin-dependent patients 5

The Kidney International guideline recommends considering reducing doses of insulin or sulfonylureas to prevent hypoglycemia when initiating SGLT2 inhibitors 5, 3
The Kidney International guideline suggests that SGLT2 inhibitors can be safely combined with metformin in CKD stages 1/2 1, 5

The Kidney International guideline warns against failing to monitor for volume depletion, especially when combined with diuretics 5, 2
The Kidney International guideline emphasizes the importance of providing patient education about potential genital mycotic infections 5
The Kidney International guideline recommends overlooking the need for sick day protocols during acute illness, and considering temporarily withholding SGLT2 inhibitors during acute illness, prolonged fasting, or surgical procedures 5, 2